Last $0.30 USD
Change Today -0.0677 / -18.41%
Volume 796.4K
RGDX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

response genetics inc (RGDX) Snapshot

Open
$0.32
Previous Close
$0.37
Day High
$0.32
Day Low
$0.25
52 Week High
01/17/14 - $1.73
52 Week Low
12/26/14 - $0.25
Market Cap
11.6M
Average Volume 10 Days
252.4K
EPS TTM
$-0.35
Shares Outstanding
38.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESPONSE GENETICS INC (RGDX)

Related News

No related news articles were found.

response genetics inc (RGDX) Related Businessweek News

No Related Businessweek News Found

response genetics inc (RGDX) Details

Response Genetics, Inc., a life science company, is engaged in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. It develops genetic tests that measure predictive factors for therapy response in tumor tissue samples. The company offers tests for non-small cell lung cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, and breast cancer patients’ tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, and ResponseDX: and Tissue of Origin test suites. It also provides HER2 mutation detection, cKIT mutation detection, MET gene amplification, and UGT1A1 SNP tests, including ROS1 FISH, ROS1 RT-PCR, c-MET, HER2 FISH, and VEGFR2. In addition, the company focuses on the development of various diagnostic tests for predicting therapy response and determining the diagnosis and prognosis of solid tumors in cancer patients. It serves community based oncologists, pathologists, physician offices, and hospitals, as well as pharmaceutical companies and cancer care centers through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

109 Employees
Last Reported Date: 03/31/14
Founded in 1999

response genetics inc (RGDX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.7K
Vice President of Research & Development
Total Annual Compensation: $333.5K
Compensation as of Fiscal Year 2013.

response genetics inc (RGDX) Key Developments

Response Genetics Receives Delisting Determination Letter From Nasdaq

On December 19, 2014, Response Genetics, Inc. received a delisting determination letter from the staff of The NASDAQ Stock Market LLC (Nasdaq) due to the Company not regaining compliance with The Nasdaq Capital Market minimum bid price of $1.00 requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) within 180 days or by December 17, 2014. The delisting determination letter also stated that the Company is not eligible for an additional 180-day extension to regain compliance with the minimum bid price rule because the Company does not meet the minimum $2,500,000 in stockholders’ equity standard for continued listing under Nasdaq Listing Rule 5550(b)(1). Pursuant to the determination letter, unless the Company requests an appeal of this determination by 4:00 p.m. (Eastern Time) on December 26, 2014, the Company’s common stock will be delisted from The Nasdaq Capital Market, trading of the Company’s common stock will be suspended at the opening of business on December 30, 2014, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. If the Company requests an appeal, the Company will be asked to provide a Hearing Panel with a plan to regain compliance. The Company’s plan would need to include a discussion of the events that the Company believes will enable it to timely regain compliance and a commitment to effect a reverse stock split, if necessary. If the Company appeals the delisting determination, the appeal will stay the suspension of the Company’s securities and the filing of the Form 25-NSE until the hearing process is completed. The Company intends to timely request a hearing to appeal the staff’s determination. While the appeal process is pending, the suspension of trading of the Company’s common stock will be stayed, and the Company’s common stock will continue to trade on the Nasdaq Capital Market until the hearing process concludes and the Hearing Panel issues a written decision. There can be no assurance that the Hearing Panel will grant the Company’s request for a suspension of delisting or continued listing on Nasdaq. If the Company’s common stock ceases to be listed for trading on the Nasdaq Capital Market, the Company expects that its common stock would be traded on the Over-the-Counter Bulletin Board on or about the same day.

Response Genetics, Inc. Secures New York State Department of Health Approval for its ResponseDX(R) Testing Services

Response Genetics Inc. received approval from the New York State Department of Health to offer, market and report results of the Company's ResponseDX® tests to healthcare providers in the State of New York. The State of New York is the third most populated state in the U.S. and the addition of this license should contribute to the continued growth of the Company's ResponseDX® sales in 2015.

Response Genetics Receives Non-Compliance Notice From Nasdaq

On November 24, 2014, Response Genetics, Inc. received a notice letter from the staff of The NASDAQ Stock Market LLC (Nasdaq) providing notification that, based on the Company’s stockholders’ equity of $2,009,700 disclosed in the Company’s Form 10-Q for the period ended September 30, 2014 (filed with the Securities and Exchange Commission on November 14, 2014), the Company does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, set forth in Listing Rule 5550(b)(1). Under applicable Nasdaq requirements, the Company has 45 calendar days to submit a plan to regain compliance with the Rule. The Company is working on a plan for submission to Nasdaq which the Company believes will enable it to regain compliance with the Rule. The Company intends to provide Nasdaq with such a plan on or before the January 8, 2015 deadline. If the plan is accepted, Nasdaq can grant the Company an extension of up to 180 calendar days from November 24, 2014 to evidence compliance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.30 USD -0.0677

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $7.17 USD +0.05
Foundation Medicine Inc $23.96 USD -0.03
NeoGenomics Inc $4.15 USD +0.12
Rosetta Genomics Ltd $2.33 USD -0.02
Veracyte Inc $9.27 USD +1.03
View Industry Companies
 

Industry Analysis

RGDX

Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit www.responsegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.